Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients
Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients, with many of their therapies still not available in suitable formulations and dosages, says business intelligence provider GBI Research.
According to the company’s latest report*, many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events and hospitalization, with up to one third of elderly emergency admissions being drug-related.
GBI Research states that off-label prescriptions are common for older patients, as pre-marketing drug trials often exclude geriatric patients and approved doses are not likely to be appropriate for the elderly.
Antipsychotic medications, for example, are regularly prescribed off-label in up to 80% of care-home patients, to manage delirium, agitation and psychosis resulting from Alzheimer’s disease and schizophrenia. However, these drugs have been associated with an increased risk of diabetes, cerebrovascular events and death, according to the report.
In 2010, the International Conference on Harmonisation (ICH) updated its E7 guidelines, which determined that the number of older patients should be representative of the study population and not limited to 100 patients, as previously indicated. Additionally, ICH E7 recommended that people aged 75 years and older should be incorporated in clinical trials, including those with comorbidities using concomitant therapies.
GBI Research believes that the development of age-appropriate formulations and doses could allow for smarter prescriptions of approved drugs, such as anti-coagulants, anti-diabetic agents, antipsychotics and analgesics in older people. Additionally, new opportunities exist for companies to develop medicines for age-related diseases, including cognitive impairment, sarcopenia and neurodegenerative diseases.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.